Robert Dempsey
Vermögen: 22 800 $ am 31.08.2026
Vermögen: 22 800 $ am 31.08.2026
Robert J.
Dempsey is currently Chairman & Chief Executive Officer at iVeena Delivery Systems, Inc. since 2019.
He is Chief Executive Officer at Ashvattha Therapeutics Inc. He will serve as Chief Executive Officer & Executive Director at OKYO Pharma Ltd. starting in 2026.
He is Director at the International Council of Ophthalmology Foundation.
Since 2021, he is President & Director at AsclepiX Therapeutics LLC.
Formerly, Mr. Dempsey was Chief Executive Officer at TearClear Corp.
from 2020 to 2021.
He was Director at Ocuterra Therapeutics, Inc. from 2018 to 2021.
He was President at BIKAM Pharmaceuticals, Inc. He was Head-Ophthalmics Business at Shire Plc.
Mr. Dempsey completed undergraduate and MBAistration degrees at Northeastern University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OKYO PHARMA LIMITED 0,03 % | 22.07.2026 | 15.000 ( 0,03 % ) | 22 800 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| WEST AFRICAN MINERALS CORP | Vorstandsvorsitzender | 05.01.2026 |
iVeena Delivery Systems, Inc.
iVeena Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology Manufactures eye drops | Vorstandsvorsitzender | 22.10.2019 |
International Council of Ophthalmology Foundation | Direktor/Vorstandsmitglied | - |
AsclepiX Therapeutics LLC
AsclepiX Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing drug technology | Präsident | 17.03.2021 |
Ashvattha Therapeutics Inc
Ashvattha Therapeutics Inc Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Vorstandsvorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
Ocuterra Therapeutics, Inc.
Ocuterra Therapeutics, Inc. Drugstore ChainsRetail Trade Manufactures drug products | Direktor/Vorstandsmitglied | 14.12.2021 |
TearClear Corp.
TearClear Corp. Medical SpecialtiesHealth Technology Develops hydrogel filter to remove potentially harmful preservatives from multi-dose topical ophthalmic products used to treat chronic diseases | Vorstandsvorsitzender | 16.03.2021 |
BIKAM Pharmaceuticals, Inc.
BIKAM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops ophthalmic pharmaceuticals products | Präsident | - |
| SHIRE | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
BIKAM Pharmaceuticals, Inc.
BIKAM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops ophthalmic pharmaceuticals products | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
OKYO Pharma Ltd.
OKYO Pharma Ltd. BiotechnologyHealth Technology Develops next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases | Health Technology |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Council of Ophthalmology Foundation | |
Ocuterra Therapeutics, Inc.
Ocuterra Therapeutics, Inc. Drugstore ChainsRetail Trade Manufactures drug products | Retail Trade |
iVeena Delivery Systems, Inc.
iVeena Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology Manufactures eye drops | Health Technology |
Ashvattha Therapeutics Inc
Ashvattha Therapeutics Inc Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
AsclepiX Therapeutics LLC
AsclepiX Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing drug technology | Commercial Services |
TearClear Corp.
TearClear Corp. Medical SpecialtiesHealth Technology Develops hydrogel filter to remove potentially harmful preservatives from multi-dose topical ophthalmic products used to treat chronic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen